Mesoblast Aligns with FDA on Biologics License Application Requirements for Ischemic Heart Failure Drug Candidate, Shares Rise 6%

MT Newswires Live

Jul 01, 2025

Mesoblast (ASX:MSB) said it aligned with the US Food and Drug Administration (FDA) on the items required for filing a Biologics License Application for its Revascor drug candidate in the treatment of patients with ischemic heart failure with reduced ejection fraction and inflammation, according to a Tuesday Australian bourse filing.

The firm plans to file by the end of the year for accelerated approval in patients with end-stage ischemic heart failure with reduced ejection fraction implanted with a left ventricular assist device.

Formal minutes for the firm's most recent Type B meeting provided by the regulator confirmed alignment with US FDA on items regarding chemistry, manufacturing, and controls, potency assays for commercial product release, as well as proposed design and primary endpoint for the confirmatory trial post-approval.

The firm's shares rose 6% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548604029"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548604029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548604029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548604029","market":"sh","top_or_hot":-1,"title":"Mesoblast Aligns with FDA on Biologics License Application Requirements for Ischemic Heart Failure Drug Candidate, Shares Rise 6%","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) said it aligned with the US Food and Drug Administration (FDA) on the items required for filing a Biologics License Application for its Revascor drug candidate in the treatment of patients with ischemic heart failure with reduced ejection fraction and inflammation, according to a Tuesday Australian bourse filing.</p><p>The firm plans to file by the end of the year for accelerated approval in patients with end-stage ischemic heart failure with reduced ejection fraction implanted with a left ventricular assist device.</p><p>Formal minutes for the firm's most recent Type B meeting provided by the regulator confirmed alignment with US FDA on items regarding chemistry, manufacturing, and controls, potency assays for commercial product release, as well as proposed design and primary endpoint for the confirmatory trial post-approval.</p><p>The firm's shares rose 6% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Aligns with FDA on Biologics License Application Requirements for Ischemic Heart Failure Drug Candidate, Shares Rise 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Aligns with FDA on Biologics License Application Requirements for Ischemic Heart Failure Drug Candidate, Shares Rise 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-01 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) said it aligned with the US Food and Drug Administration (FDA) on the items required for filing a Biologics License Application for its Revascor drug candidate in the treatment of patients with ischemic heart failure with reduced ejection fraction and inflammation, according to a Tuesday Australian bourse filing.</p><p>The firm plans to file by the end of the year for accelerated approval in patients with end-stage ischemic heart failure with reduced ejection fraction implanted with a left ventricular assist device.</p><p>Formal minutes for the firm's most recent Type B meeting provided by the regulator confirmed alignment with US FDA on items regarding chemistry, manufacturing, and controls, potency assays for commercial product release, as well as proposed design and primary endpoint for the confirmatory trial post-approval.</p><p>The firm's shares rose 6% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2548604029","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548604029","pubTimestamp":1751335734,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  said it aligned with the US Food and Drug Administration  on the items required for filing a Biologics License Application for its Revascor drug candidate in the treatment of patients with ischemic heart failure with reduced ejection fraction and inflammation, according to a Tuesday Australian bourse filing.The firm plans to file by the end of the year for accelerated approval in patients with end-stage ischemic heart failure with reduced ejection fraction implanted with a left ventricular assist device.Formal minutes for the firm's most recent Type B meeting provided by the regulator confirmed alignment with US FDA on items regarding chemistry, manufacturing, and controls, potency assays for commercial product release, as well as proposed design and primary endpoint for the confirmatory trial post-approval.The firm's shares rose 6% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited","MSB.AU":"MESOBLAST LTD","BK4139":"生物科技","BK7067":"生物科技","BK7508":"医药生物股","BK7501":"新冠治疗股"},"translate_title":"Mesoblast与FDA就缺血性心力衰竭候选药物的生物制品许可申请要求保持一致，股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1,"MSB.AU":0.9},"content_text":"Mesoblast (ASX:MSB) said it aligned with the US Food and Drug Administration (FDA) on the items required for filing a Biologics License Application for its Revascor drug candidate in the treatment of patients with ischemic heart failure with reduced ejection fraction and inflammation, according to a Tuesday Australian bourse filing.The firm plans to file by the end of the year for accelerated approval in patients with end-stage ischemic heart failure with reduced ejection fraction implanted with a left ventricular assist device.Formal minutes for the firm's most recent Type B meeting provided by the regulator confirmed alignment with US FDA on items regarding chemistry, manufacturing, and controls, potency assays for commercial product release, as well as proposed design and primary endpoint for the confirmatory trial post-approval.The firm's shares rose 6% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}